loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Inavolisib

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Inavolisib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Priority Review: Genentech's Inavolisib For PIK3CA+ Breast Cancer
    FDA Priority Review: Genentech's Inavolisib For PIK3CA+ Breast Cancer

    29 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240528294074/en

    BUSINESSWIRE
    29 May 2024
    Share Share
    FDA Priority Review: Roche's Inavolisib For PIK3CA+ Breast Cancer
    FDA Priority Review: Roche's Inavolisib For PIK3CA+ Breast Cancer

    29 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/29/2889533/0/en/FDA-grants-Priority-Review-to-Roche-s-inavolisib-for-advanced-hormone-receptor-positive-HER2-negative-breast-cancer-with-a-PIK3CA-mutation.html

    GLOBENEWSWIRE
    29 May 2024
    Share Share
    FDA Grants Roche's Inavolisib Breakthrough Therapy For PIK3CA Breast Cancer
    FDA Grants Roche's Inavolisib Breakthrough Therapy For PIK3CA Breast Cancer

    21 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/21/2885235/0/en/FDA-grants-Breakthrough-Therapy-Designation-to-Roche-s-inavolisib-for-advanced-hormone-receptor-positive-HER2-negative-breast-cancer-with-a-PIK3CA-mutation.html

    GLOBENEWSWIRE
    21 May 2024
    Share Share
    FDA Grants Genentech's Inavolisib Breakthrough For PIK3CA Breast Cancer
    FDA Grants Genentech's Inavolisib Breakthrough For PIK3CA Breast Cancer

    21 May 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240520522522/en

    BUSINESSWIRE
    21 May 2024
    Share Share